Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 24 | 2016 | 385 | 2.620 |
Why?
|
| Brain Concussion | 16 | 2022 | 62 | 2.090 |
Why?
|
| Schizophrenia | 10 | 2016 | 31 | 1.520 |
Why?
|
| Neuropsychological Tests | 30 | 2020 | 371 | 1.450 |
Why?
|
| Brain Injuries | 13 | 2015 | 93 | 1.010 |
Why?
|
| Athletic Injuries | 9 | 2020 | 82 | 0.950 |
Why?
|
| Schizophrenic Psychology | 5 | 2012 | 9 | 0.750 |
Why?
|
| Hockey | 8 | 2015 | 10 | 0.680 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2016 | 1328 | 0.680 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2018 | 226 | 0.670 |
Why?
|
| Alzheimer Disease | 10 | 2012 | 327 | 0.650 |
Why?
|
| Brain | 11 | 2018 | 951 | 0.640 |
Why?
|
| Hippocampus | 4 | 2015 | 171 | 0.590 |
Why?
|
| Memory Disorders | 8 | 2016 | 54 | 0.570 |
Why?
|
| Memory | 9 | 2018 | 190 | 0.510 |
Why?
|
| Diffusion Tensor Imaging | 6 | 2020 | 29 | 0.490 |
Why?
|
| Awareness | 3 | 2009 | 29 | 0.490 |
Why?
|
| Adult | 40 | 2022 | 9345 | 0.490 |
Why?
|
| Humans | 72 | 2022 | 32005 | 0.490 |
Why?
|
| Amnesia | 3 | 2010 | 8 | 0.480 |
Why?
|
| Male | 53 | 2020 | 19165 | 0.470 |
Why?
|
| Female | 53 | 2020 | 19959 | 0.470 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2018 | 53 | 0.440 |
Why?
|
| Cognition | 6 | 2017 | 555 | 0.440 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2018 | 47 | 0.430 |
Why?
|
| Frontal Lobe | 5 | 2010 | 36 | 0.430 |
Why?
|
| Young Adult | 18 | 2022 | 2636 | 0.380 |
Why?
|
| Memory, Short-Term | 5 | 2017 | 60 | 0.360 |
Why?
|
| Automation | 1 | 2010 | 31 | 0.350 |
Why?
|
| Athletes | 6 | 2020 | 69 | 0.340 |
Why?
|
| Adolescent | 16 | 2022 | 3539 | 0.330 |
Why?
|
| Head Protective Devices | 6 | 2015 | 48 | 0.330 |
Why?
|
| Verbal Behavior | 2 | 2008 | 9 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2016 | 97 | 0.320 |
Why?
|
| Septum Pellucidum | 1 | 2007 | 2 | 0.290 |
Why?
|
| Mental Disorders | 3 | 2013 | 121 | 0.270 |
Why?
|
| Head | 3 | 2022 | 51 | 0.270 |
Why?
|
| Reaction Time | 6 | 2016 | 117 | 0.270 |
Why?
|
| Methylphenidate | 2 | 2016 | 36 | 0.260 |
Why?
|
| Geriatric Assessment | 1 | 2008 | 390 | 0.260 |
Why?
|
| Psychomotor Performance | 4 | 2016 | 99 | 0.250 |
Why?
|
| Middle Aged | 20 | 2018 | 11817 | 0.240 |
Why?
|
| Borderline Personality Disorder | 1 | 2004 | 3 | 0.240 |
Why?
|
| Parietal Lobe | 2 | 2006 | 13 | 0.230 |
Why?
|
| Amygdala | 2 | 2015 | 61 | 0.230 |
Why?
|
| Hypothyroidism | 1 | 2003 | 12 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 1062 | 0.220 |
Why?
|
| Psychotic Disorders | 3 | 2011 | 11 | 0.220 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2015 | 29 | 0.220 |
Why?
|
| Executive Function | 3 | 2016 | 57 | 0.220 |
Why?
|
| Depressive Disorder | 1 | 2003 | 75 | 0.220 |
Why?
|
| Brain Mapping | 4 | 2011 | 178 | 0.200 |
Why?
|
| Problem Solving | 4 | 2011 | 28 | 0.200 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2011 | 27 | 0.190 |
Why?
|
| Football | 4 | 2020 | 77 | 0.190 |
Why?
|
| Dementia | 1 | 2003 | 252 | 0.180 |
Why?
|
| Psychometrics | 3 | 2016 | 137 | 0.180 |
Why?
|
| Models, Biological | 2 | 2014 | 392 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 112 | 0.180 |
Why?
|
| Emotions | 2 | 2017 | 58 | 0.180 |
Why?
|
| Models, Neurological | 3 | 2018 | 117 | 0.170 |
Why?
|
| Accidents, Traffic | 1 | 2022 | 195 | 0.170 |
Why?
|
| Acceleration | 5 | 2022 | 65 | 0.170 |
Why?
|
| Aged | 14 | 2012 | 10301 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 762 | 0.170 |
Why?
|
| Corpus Callosum | 2 | 2011 | 18 | 0.160 |
Why?
|
| Post-Concussion Syndrome | 1 | 2018 | 2 | 0.160 |
Why?
|
| Attention | 5 | 2016 | 83 | 0.160 |
Why?
|
| Veterans | 2 | 2016 | 68 | 0.160 |
Why?
|
| Aggression | 2 | 2015 | 30 | 0.160 |
Why?
|
| Students | 3 | 2016 | 172 | 0.160 |
Why?
|
| Health Surveys | 1 | 2018 | 196 | 0.150 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 6 | 0.150 |
Why?
|
| Thalamus | 2 | 2015 | 33 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 42 | 0.140 |
Why?
|
| Disease Progression | 3 | 2010 | 594 | 0.140 |
Why?
|
| Malingering | 1 | 2016 | 5 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 881 | 0.140 |
Why?
|
| Epilepsies, Partial | 1 | 2016 | 9 | 0.140 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 10 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2265 | 0.140 |
Why?
|
| Afghan Campaign 2001- | 1 | 2016 | 14 | 0.140 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2008 | 79 | 0.140 |
Why?
|
| Universities | 2 | 2015 | 145 | 0.140 |
Why?
|
| Health Status | 1 | 2018 | 399 | 0.130 |
Why?
|
| Social Behavior | 1 | 2016 | 65 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2008 | 898 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 76 | 0.130 |
Why?
|
| Galantamine | 1 | 2015 | 1 | 0.130 |
Why?
|
| Neostriatum | 1 | 2015 | 22 | 0.130 |
Why?
|
| Regional Blood Flow | 1 | 2015 | 86 | 0.130 |
Why?
|
| Brain Injury, Chronic | 1 | 2015 | 1 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2007 | 8 | 0.130 |
Why?
|
| Diffuse Axonal Injury | 1 | 2015 | 3 | 0.130 |
Why?
|
| Health Priorities | 1 | 2015 | 15 | 0.130 |
Why?
|
| Policy Making | 1 | 2015 | 20 | 0.130 |
Why?
|
| Violence | 1 | 2015 | 15 | 0.130 |
Why?
|
| Functional Laterality | 3 | 2010 | 56 | 0.120 |
Why?
|
| Recovery of Function | 2 | 2016 | 199 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 93 | 0.120 |
Why?
|
| Safety | 1 | 2015 | 77 | 0.120 |
Why?
|
| Statistics as Topic | 3 | 2010 | 108 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2016 | 221 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2020 | 1817 | 0.120 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 185 | 0.120 |
Why?
|
| Suicide | 1 | 2014 | 20 | 0.110 |
Why?
|
| Linear Models | 2 | 2016 | 447 | 0.110 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2013 | 2 | 0.110 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2013 | 7 | 0.110 |
Why?
|
| Dopamine Agonists | 2 | 2011 | 28 | 0.110 |
Why?
|
| Contrast Sensitivity | 1 | 2012 | 4 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2012 | 23 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2016 | 525 | 0.100 |
Why?
|
| Software | 2 | 2010 | 123 | 0.100 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 37 | 0.100 |
Why?
|
| Time Factors | 3 | 2015 | 2149 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 130 | 0.100 |
Why?
|
| Guanfacine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Bromocriptine | 1 | 2011 | 1 | 0.090 |
Why?
|
| Emotional Intelligence | 1 | 2010 | 1 | 0.090 |
Why?
|
| Obsessive Behavior | 1 | 2010 | 3 | 0.090 |
Why?
|
| Compulsive Behavior | 1 | 2010 | 4 | 0.090 |
Why?
|
| Brain Stem | 1 | 2010 | 20 | 0.090 |
Why?
|
| Aging | 2 | 2007 | 946 | 0.090 |
Why?
|
| Illness Behavior | 1 | 2009 | 2 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2010 | 38 | 0.080 |
Why?
|
| Genotype | 4 | 2016 | 733 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 218 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 132 | 0.080 |
Why?
|
| Risk Factors | 5 | 2014 | 3876 | 0.080 |
Why?
|
| Comorbidity | 3 | 2018 | 566 | 0.080 |
Why?
|
| Language Tests | 1 | 2008 | 5 | 0.080 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2008 | 50 | 0.080 |
Why?
|
| Antipsychotic Agents | 2 | 2007 | 27 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2013 | 780 | 0.080 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 30 | 0.070 |
Why?
|
| Evoked Potentials | 1 | 2007 | 17 | 0.070 |
Why?
|
| Quality of Life | 3 | 2018 | 946 | 0.070 |
Why?
|
| Anisotropy | 2 | 2020 | 11 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2006 | 14 | 0.070 |
Why?
|
| Fornix, Brain | 1 | 2006 | 7 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2006 | 16 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 517 | 0.070 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 95 | 0.070 |
Why?
|
| Pseudobulbar Palsy | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 21 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2004 | 18 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 31 | 0.060 |
Why?
|
| Verbal Learning | 1 | 2004 | 8 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 3306 | 0.060 |
Why?
|
| Indans | 1 | 2004 | 31 | 0.060 |
Why?
|
| Thyroid Function Tests | 1 | 2003 | 4 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2003 | 21 | 0.060 |
Why?
|
| Thyroxine | 1 | 2003 | 16 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2003 | 31 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 36 | 0.060 |
Why?
|
| Affect | 1 | 2004 | 69 | 0.060 |
Why?
|
| Piperidines | 1 | 2004 | 118 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2011 | 463 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 15 | 0.050 |
Why?
|
| Reference Values | 3 | 2007 | 246 | 0.050 |
Why?
|
| Alleles | 2 | 2016 | 248 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 301 | 0.050 |
Why?
|
| Child | 3 | 2015 | 2438 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2002 | 87 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1531 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 458 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 767 | 0.050 |
Why?
|
| Hospitalization | 1 | 2004 | 470 | 0.050 |
Why?
|
| Oxygen | 2 | 2011 | 142 | 0.040 |
Why?
|
| Observer Variation | 2 | 2012 | 105 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 663 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 582 | 0.040 |
Why?
|
| Trauma Severity Indices | 2 | 2011 | 49 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 918 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2009 | 18 | 0.040 |
Why?
|
| Depression | 2 | 2016 | 444 | 0.040 |
Why?
|
| Syndrome | 2 | 2010 | 72 | 0.040 |
Why?
|
| Task Performance and Analysis | 2 | 2007 | 53 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 2282 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2018 | 220 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 297 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3509 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2016 | 73 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2007 | 3 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 208 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2015 | 16 | 0.030 |
Why?
|
| Minnesota | 1 | 2015 | 22 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 41 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 560 | 0.030 |
Why?
|
| United States | 2 | 2014 | 3939 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 240 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 172 | 0.030 |
Why?
|
| Skiing | 1 | 2013 | 2 | 0.030 |
Why?
|
| Track and Field | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mental Health Services | 1 | 2014 | 31 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 76 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 63 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 545 | 0.030 |
Why?
|
| Paranoid Disorders | 1 | 2013 | 1 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 217 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2012 | 6 | 0.030 |
Why?
|
| Unconsciousness | 1 | 2012 | 5 | 0.030 |
Why?
|
| Dizziness | 1 | 2012 | 12 | 0.030 |
Why?
|
| Neck Pain | 1 | 2012 | 6 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2013 | 65 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 495 | 0.030 |
Why?
|
| Headache | 1 | 2012 | 75 | 0.030 |
Why?
|
| New Hampshire | 1 | 2011 | 5 | 0.030 |
Why?
|
| Sports Equipment | 1 | 2011 | 5 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 253 | 0.020 |
Why?
|
| Telemetry | 1 | 2011 | 26 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 80 | 0.020 |
Why?
|
| Rotation | 1 | 2011 | 47 | 0.020 |
Why?
|
| Atrophy | 1 | 2011 | 46 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1188 | 0.020 |
Why?
|
| Prolactin | 1 | 2011 | 10 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 67 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 82 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 95 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 125 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 2010 | 5 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 981 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 10 | 0.020 |
Why?
|
| Self Concept | 1 | 2009 | 43 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 632 | 0.020 |
Why?
|
| DNA Replication | 1 | 2008 | 34 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 220 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 220 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 3990 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 4 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2007 | 28 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cephalometry | 1 | 2007 | 19 | 0.020 |
Why?
|
| Receptors, Catecholamine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Apolipoprotein E3 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2007 | 94 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 781 | 0.020 |
Why?
|
| Catecholamines | 1 | 2006 | 18 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 876 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 109 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2006 | 63 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 71 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2005 | 27 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 126 | 0.010 |
Why?
|
| Vocabulary | 1 | 2004 | 1 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 2004 | 2 | 0.010 |
Why?
|
| Semantics | 1 | 2004 | 9 | 0.010 |
Why?
|
| Intelligence | 1 | 2004 | 5 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 42 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 184 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 293 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 181 | 0.010 |
Why?
|
| Mass Screening | 1 | 2005 | 263 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 191 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 835 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 726 | 0.010 |
Why?
|